The Beauty Health Company (SKIN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 37/100 (MEDIUM), 193.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 11.05% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
- SkinHealth Systems Unveils New Hydrafacial™ and HydraScalp® with Keravive™ Clinical Data at the 2026 Science of Skin Summit
- Hydrafacial Expands Treatment Personalization and Elevates Results with Two New Treatment Enhancers
- How Investors Are Reacting To Merit Medical Systems (MMSI) New Global Operations Leadership Transition
- SkinHealth Systems Launches Hydrafacial Impact to Help Providers Accelerate Practice Growth
- SkinHealth Systems Inc. (SKIN) International Revenue Performance Explored
- Beauty Health Q2 Earnings Call Highlights
- SkinHealth Systems Inc. (SKIN) Reports Q2 Earnings: What Key Metrics Have to Say
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Effectiveness of a Workplace Web-based Multi-component Intervention on Lifestyle, Health, and Work Productivity in Beauty Consultants: A Randomized Controlled Trial. — J Occup Environ Med 2026 Oct 1 PMID 41944784
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for The Beauty Health Company.
Full SKIN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.